Wendy J. De Leng

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 07, 2026

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 10, 2026

Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study.

Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study.

Journal: The Lancet. Haematology

Published: January 08, 2026

Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk.

Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk.

Journal: Cancers

Published: December 08, 2025

Evaluation of homologous recombination testing in ovarian carcinoma.

Evaluation of homologous recombination testing in ovarian carcinoma.

Journal: Virchows Archiv : an international journal of pathology

Published: November 27, 2025

Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients.

Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 17, 2025

Prospective evaluation of genomics-guided off-label treatment.

Prospective evaluation of genomics-guided off-label treatment.

Journal: Nature

Published: September 02, 2025

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 16, 2025

Clinical implications of whole genome sequencing in metastatic colorectal cancer.

Clinical implications of whole genome sequencing in metastatic colorectal cancer.

Journal: Oncogene

Published: June 10, 2025

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol.

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol.

Journal: International journal of cancer

Published: March 13, 2025

Ameloblastic Fibro-Odontoma with an FGFR1 Mutation: A Case Report.

Ameloblastic Fibro-Odontoma with an FGFR1 Mutation: A Case Report.

Journal: Head and neck pathology

Published: December 14, 2024

Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours.

Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours.

Journal: EBioMedicine

Published: November 07, 2024

Showing 1-12 of 71

Last Updated: 09/26/2026